Sugi Predict

Sugi Predict / Compounds / SCHEMBL1557048

SCHEMBL1557048

SCHEMBL1557048

Cc1nc(-c2ccc(Br)cc2)oc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TARBP2 Q15633 1/20 0.53
▸ NPC1 O15118 7/20 0.46
▸ RAB9A P51151 7/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ TSHR P16473 3/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ HPGD P15428 2/20 0.46
▸ GAA P10253 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ DGAT1 O75907 1/20 0.44
▸ RXFP1 Q9HBX9 2/20 0.44
▸ KMT2A Q03164 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ NR1H4 Q96RI1 1/20 0.42
▸ HDAC6 Q9UBN7 3/20 0.41
▸ HDAC1 Q13547 2/20 0.41
▸ HDAC8 Q9BY41 2/20 0.41
▸ SMPD1 P17405 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2706143 0.83 NPC1 (0.52) TARBP2NPC1RAB9AKDM4ETSHR
SCHEMBL5539515 0.81 NPC1 (0.44) TARBP2NPC1RAB9AKDM4ETSHR
SCHEMBL5534902 0.80 KDM4E (0.59) TARBP2NPC1RAB9AKDM4ETSHR
SCHEMBL9862893 0.80 NPC1 (0.51) NPC1RAB9AKDM4ESMN1; SMN2GAA
SCHEMBL5543997 0.80 NPC1 (0.52) NPC1RAB9AKDM4ETSHRSMN1; SMN2
SCHEMBL24125061 0.80 RAB9A (0.52) NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL14431592 0.80 GAA (0.54) TARBP2NPC1RAB9AKDM4ETSHR
Ethane SCHEMBL28752838 0.79 TARBP2 (0.52) TARBP2NPC1RAB9AKDM4ETSHR
SCHEMBL436384 0.79 GAA (0.57) TARBP2NPC1RAB9AKDM4ETSHR
SCHEMBL13633790 0.78 TP53 (0.50) NPC1RAB9AKDM4ETSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210121449-A1 NOVEL OXAZOLIDINONE DERIVATIVES DONG A ST CO LTD (KR) 2021-04-29 — — US disclosed
US-20200078345-A1 NOVEL OXAZOLIDINONE DERIVATIVES DONG A ST CO LTD (KR) 2020-03-12 — — US disclosed
US-20180344716-A1 NOVEL OXAZOLIDINONE DERIVATIVES DONG A ST CO LTD (KR) 2018-12-06 — — US disclosed
US-20170333414-A1 NOVEL OXAZOLIDINONE DERIVATIVES DONG A ST CO LTD (KR) 2017-11-23 — — US disclosed
US-20170049763-A1 NOVEL OXAZOLIDINONE DERIVATIVES DONG A ST CO LTD (KR) 2017-02-23 — — US disclosed
US-9163043-B2 Oxazolidinone derivatives DONG-A ST CO., LTD. (KR) 2015-10-20 — — US disclosed
US-20140350059-A1 NOVEL OXAZOLIDINONE DERIVATIVES DONG A ST CO LTD (KR) 2014-11-27 — — US disclosed
US-20130281492-A1 NOVEL OXAZOLIDINONE DERIVATIVES TRIUS THERAPEUTICS, INC. 2013-10-24 — — US disclosed
US-8420676-B2 Oxazolidinone derivatives DONG-A PHARMACEUTICALS CO. LTD. (KR) 2013-04-16 — — US disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 — — EP disclosed
WO-2005058886-A1 NOVEL OXAZOLIDINONE DERIVATIVES DONG-A PHARM.CO.,LTD. (KR) 2005-06-30 — — WO disclosed
EP-0921800-B1 SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES BRISTOL MYERS SQUIBB CO (US) 2004-04-14 — — EP disclosed
EP-0702012-B1 Substituted isoxazole sulfonamides and their use as endothelin antagonists BRISTOL MYERS SQUIBB CO (US) 2003-10-15 — — EP disclosed
EP-0921800-A4 SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES BRISTOL MYERS SQUIBB CO (US) 2000-12-06 — — EP disclosed
EP-0921800-A1 SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES BRISTOL-MYERS SQUIBB COMPANY (US) 1999-06-16 — — EP disclosed
US-5846990-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB CO. (US) 1998-12-08 — — US disclosed
US-5827869-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB COMPANY (US) 1998-10-27 — — US disclosed
WO-1997029748-A1 SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES BRISTOL-MYERS SQUIBB COMPANY (US) 1997-08-21 — — WO disclosed
US-5612359-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB COMPANY (US) 1997-03-18 — — US disclosed
EP-0702012-A1 Substituted isoxazole sulfonamides and their use as endothelin antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 1996-03-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170049763-A1 NOVEL OXAZOLIDINONE DERIVATIVES ALPI, OXA1L, SI TARBP2 4816/4885NPC1 2874/4885RAB9A 3975/4885
US-20130281492-A1 NOVEL OXAZOLIDINONE DERIVATIVES ALPI, OXA1L, SI TARBP2 4816/4885NPC1 2874/4885RAB9A 3975/4885
US-20210121449-A1 NOVEL OXAZOLIDINONE DERIVATIVES ALPI, OXA1L, SI TARBP2 4816/4885NPC1 2874/4885RAB9A 3975/4885
US-20200078345-A1 NOVEL OXAZOLIDINONE DERIVATIVES ALPI, OXA1L, SI TARBP2 4816/4885NPC1 2874/4885RAB9A 3975/4885
US-20170333414-A1 NOVEL OXAZOLIDINONE DERIVATIVES ALPI, OXA1L, SI TARBP2 4816/4885NPC1 2874/4885RAB9A 3975/4885
US-20140350059-A1 NOVEL OXAZOLIDINONE DERIVATIVES ALPI, OXA1L, SI TARBP2 4816/4885NPC1 2874/4885RAB9A 3975/4885
US-20180344716-A1 NOVEL OXAZOLIDINONE DERIVATIVES ALPI, OXA1L, SI TARBP2 4816/4885NPC1 2874/4885RAB9A 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.